Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Assertio Therapeutics Inc (ASRT)

Assertio Therapeutics Inc (ASRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,847
  • Shares Outstanding, K 96,252
  • Annual Sales, $ 124,960 K
  • Annual Income, $ -21,580 K
  • EBIT $ 14 M
  • EBITDA $ 41 M
  • 60-Month Beta 0.55
  • Price/Sales 0.60
  • Price/Cash Flow 15.90
  • Price/Book 0.71
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $0.11 on 11/10/25
  • Next Earnings Date 03/11/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 384.18% (+254.75%)
  • Historical Volatility 62.48%
  • IV Percentile 92%
  • IV Rank 46.95%
  • IV High 737.85% on 09/18/25
  • IV Low 71.16% on 08/12/25
  • Expected Move (DTE 8) 0.2550 (32.69%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 38
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 24,923
  • Open Int (30-Day) 23,681
  • Expected Range 0.5250 to 1.0350

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -81.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6502 +19.96%
on 11/25/25
0.9500 -17.89%
on 11/11/25
-0.0210 (-2.62%)
since 11/10/25
3-Month
0.6502 +19.96%
on 11/25/25
1.0100 -22.77%
on 09/18/25
-0.0252 (-3.13%)
since 09/10/25
52-Week
0.5100 +52.94%
on 04/09/25
1.0100 -22.77%
on 09/18/25
-0.1758 (-18.39%)
since 12/10/24

Most Recent Stories

More News
Assertio: Q3 Earnings Snapshot

Assertio: Q3 Earnings Snapshot

ASRT : 0.7800 (-1.02%)
Assertio Reports Third Quarter 2025 Financial Results

Advanced Integration Efforts to Consolidate Subsidiaries and Pulled Forward Two Quarters of Rolvedon Demand Promotes Paul Schwichtenberg to President...

ASRT : 0.7800 (-1.02%)
Assertio Announces Leadership Transition

Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within...

ASRT : 0.7800 (-1.02%)
Assertio Therapeutics Amends ROLVEDON Supply Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Assertio...

ASRT : 0.7800 (-1.02%)
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025

PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  is investigating securities fraud claims against  Spectrum...

ASRT : 0.7800 (-1.02%)
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy Study addresses lack of awareness and...

ASRT : 0.7800 (-1.02%)
DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025

PHILADELPHIA , Sept. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  is investigating securities fraud claims against  Spectrum...

ASRT : 0.7800 (-1.02%)
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients...

ASRT : 0.7800 (-1.02%)
SPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025

PHILADELPHIA , Sept. 8, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  is investigating securities fraud claims against  Spectrum...

SPPI : 1.0300 (unch)
ASRT : 0.7800 (-1.02%)
Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025

LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings...

ASRT : 0.7800 (-1.02%)

Business Summary

Assertio Holdings Inc. is a specialty pharmaceutical company. Its portfolio consists of branded prescription neurology, inflammation and pain medications. The company's business development includes acquisitions, licensing and mergers. Assertio Holdings Inc., formerly known as Assertio Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 0.8288
2nd Resistance Point 0.8144
1st Resistance Point 0.7972
Last Price 0.7800
1st Support Level 0.7656
2nd Support Level 0.7512
3rd Support Level 0.7340

See More

52-Week High 1.0100
Fibonacci 61.8% 0.8190
Last Price 0.7800
Fibonacci 50% 0.7600
Fibonacci 38.2% 0.7010
52-Week Low 0.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar